AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A Pair Of ‘Wild Card’ Studies Pay Off
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
